Cogent Biosciences Inc

For the period ended Sep 30, 2024. Filed Nov 12, 2024.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2024 · Filed Nov 12, 2024

COGT$31.64-5.7%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share amounts)

	Three Months Ended September 30,		Nine Months Ended September 30,
	2024	2023	2024	2023
Operating expenses:
Research and development	$63,614	$50,127	$170,613	$125,036
General and administrative	11,800	9,453	31,592	24,866
Total operating expenses	75,414	59,580	202,205	149,902
Loss from operations	(75,414)	(59,580)	(202,205)	(149,902)
Other income:
Interest income	4,779	4,198	14,229	9,207
Other income, net	1	—	44	950
Change in fair value of CVR liability	—	—	—	1,700
Total other income, net	4,780	4,198	14,273	11,857
Net loss	$(70,634)	$(55,382)	$(187,932)	$(138,045)
Net loss per share attributable to common stockholders, basic and diluted	$(0.64)	$(0.64)	$(1.85)	$(1.79)
Weighted average common shares outstanding, basic and diluted	110,165,580	86,165,951	101,435,402	77,274,580
Comprehensive loss:
Net loss	$(70,634)	$(55,382)	$(187,932)	$(138,045)
Other comprehensive income (loss):
Net unrealized gains (losses) on marketable securities	1,088	(75)	650	(68)
Total other comprehensive income (loss)	1,088	(75)	650	(68)
Comprehensive loss	$(69,546)	$(55,457)	$(187,282)	$(138,113)

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.